About 200 reports

  • KEY EVENTS AND TRENDS TO WATCH FOR IN GASTROINTESTINAL CANCERS
  • OF CONTENTS

The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area Summary GlobalData’s "The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area", provides an insight-rich overview of the key events and trends that our analysts expect to...

  • Hepatitis
  • United States
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group

Dietary factors have a substantial influence on the risk of cancers of the gastrointestinal tract.

  • Hepatitis
  • World
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.
  • GASTROINTESTINAL STROMAL TUMOR (GIST) - PIPELINE BY ARRAY BIOPHARMA INC, H1 2018
  • GASTROINTESTINAL STROMAL TUMOR (GIST) - PIPELINE BY BOSTON BIOMEDICAL INC, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology)...

  • Hepatitis
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.

Examples include gastrointestinal haemorrhage or intracranial haemorrhage.

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.

Cytomegalovirus - Background - Chorioretinitis - Gastrointestinal - Central Nervous System Disease - Diagnostic Tests - Vaccines and Drugs d.

  • Hepatitis
  • HIV AIDS
  • Infectious Disease
  • United States
  • World

Medication is often lifelong, and long-standing treatment can eventually lead to complications such as osteoporosis, pneumonia and gastrointestinal infection.

  • Cancer
  • Hepatitis
  • Sweden
  • Karolinska Institutet Holding
  • Takeda Pharmaceutical Company Limited

You can easily book an appointment with one online.

  • Hepatitis
  • World
  • Forecast
  • Eli Lilly & Co.
  • Pfizer Inc.

The auto exports exceeded over ## million each year.

  • Diagnostic Reagent
  • Hepatitis
  • China
  • Demand
  • Biosino Bio-Technology & Science Inc

Examples include gastrointestinal haemorrhage or intracranial haemorrhage.

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.
  • 2.7.2 CHRONIC STAGE

A study of ## patients showed that after eight years, HCC developed in ##% of patients, ascites in ##%, gastrointestinal bleeding in ##% and hepatic encephalopathy in ##% (Hepatitis C Trust, 2011).

  • Hepatitis
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Roche Group

Genotype ## is the most common HCV.

  • Hepatitis
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

The auto exports exceeded over ## million each year.

  • Hepatitis
  • China
  • Demand
  • Beijing Union Pharmaceutical Co., Ltd.
  • Sichuan Medco Pharmaceutical Stock Co., Ltd.

(USA) ##.

  • Hepatitis
  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • Market Shares

No. ## Lize East## Road, Chaoyang District, Beijing, P. R.

  • Hepatitis
  • China
  • Beijing Union Pharmaceutical Co., Ltd.
  • Livzon Group
  • Sichuan Medco Pharmaceutical Stock Co., Ltd.
  • 4.6 Disease Progression
  • HEPATITIS C THERAPEUTICS MARKET, RISK FACTORS FOR FIBROSIS

A STUDY OF ## PATIENTS SHOWED THAT AFTER EIGHT YEARS, HEPATOCELLULAR CARCINOMA (HCC) DEVELOPED IN ##% OF PATIENTS, ASCITES IN ##%, GASTROINTESTINAL BLEEDING IN ##% AND HEPATIC ENCEPHALOPATHY IN ##% (HEPATITIS C TRUST, 2011).

  • Hepatitis
  • World
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • Hepatitis
  • China
  • Biosino Bio-Technology & Science Inc
  • Livzon Group

Used in endoscopic surgeries and for individuals who require gastrointestinal recanalization.

  • Hepatitis
  • World
  • bioMerieux S.A.
  • Grifols, S.A.
  • Roche Group
  • ALERE: KEY TAKEAWAYS

Alere' s POC products are available for infectious diseases such as respiratory syncytial virus (RSV), influenza, tuberculosis, pneumonia, HIV, AIDS, gastrointestinal disease, dengue, and malaria.

  • Hepatitis
  • World
  • Alere Inc.
  • DiaSorin S.p.A.
  • Roche Group

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • Hepatitis
  • China
  • Biosino Bio-Technology & Science Inc
  • Livzon Group
  • COMMON ROUTES OF VIRAL ENTRY
  • 2.3 Hepatitis C Virus

THESE CONDITIONS MAY BE ASSOCIATED WITH SYMPTOMS SUCH AS JAUNDICE, HEMATEMESIS, DARK-COLORED URINE OR FECES, EDEMA AND GASTROINTESTINAL SYMPTOMS (NHS, 2015C).

  • Hepatitis
  • Therapy
  • World
  • Market Size
  • Gilead Sciences, Inc.
  • PFIZER HALTED GLOBAL DEVELOPMENT OF SUTENT FOR HCC IN 2010
  • Product profile (late stage): Stivarga

The success of Nexavar has boosted the development of new targeted therapies, approvals of which will drive the growth of the hepatocellular cancer market. This report addresses the following questions: - Which products will drive the growth of the hepatocellular cancer market? - What is the commercial potential for...

  • Hepatitis
  • Japan
  • United States
  • ArQule, Inc.
  • Eli Lilly & Co.
  • STIVARGA SWOT ANALYSIS

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA; ##: ##-##.

  • Hepatitis
  • Celsion Corporation
  • Eli Lilly & Co.
  • GlobalData's company
  • ThermoDox® group
  • MARKET OVERVIEW

BY 2050, A GREATER SHARE ## U. S.

  • Diagnostic Reagent
  • Hepatitis
  • China
  • Abbott Laboratories, Inc.
  • Roche Group
  • DORMANT PRODUCTS, H1 2018

IT ACTS BY TARGETING TGF-BETA ## RECEPTOR.

  • Hepatitis
  • United States
  • World
  • Product Initiative
  • Eli Lilly & Co.
  • PIPELINE BY HANMI PHARMACEUTICALS CO LTD, H1 2018
  • PIPELINE BY GENOSCO INC, H1 2018

It was also under development for the treatment of solid tumors including recurrent glioblastoma multiforme (GBM), advanced gastrointestinal stromal tumor (GIST).

  • Cancer
  • Hepatitis
  • United States
  • Product Initiative
  • Eisai Co., Ltd.
  • Featured News & Press Releases
  • Products under Development by Companies, H1 2017

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Hepatitis
  • Turkey
  • World
  • Product Initiative
  • Eli Lilly & Co.
  • Jan 15, 2018: Data To Be Presented On cabozantinib (Cabometyx) At 2018 ASCO Gastrointestinal Symposium
  • Dec 13, 2017: Bayer receives approval in China for Stivarga (regorafenib) for the second-line systemic Treatment of liver cancer

Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Pipeline Review, H1 2018 Summary According...

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • Exelixis, Inc.
  • Clinical Trial profile. 119 Trial Title
  • Clinical Trial profile. 39 Trial Title

Boehringer Sohn AG & Co KG ## ## ## ## ## ## Nitto Denko Corp ## ## ## ## ## ## Galectin Therapeutics Inc ## ## ## ## ## ## F.

  • Clinical Trial
  • Drug Discovery And Development
  • Hepatitis
  • World
  • Product Initiative
  • L-P - DRUG PROFILE
  • SHR-1210 - DRUG PROFILE

Median follow-up was ## ## months (IQR ## ##-## ##).

  • Hepatitis
  • Lung Cancer
  • Therapy
  • United States
  • Company Operations
  • Clinical Trial profile. 61 Trial Title
  • Clinical Trial profile. 110 Trial Title

## ## Germany ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## Italy Source: GlobalData' s Pharma Intelligence Center Clinical

  • Clinical Trial
  • Drug Discovery And Development
  • Hepatitis
  • Therapy
  • World